Celene Balido

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Chronic Kidney Disease

Prognostic Factors

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)